SG11201601250TA - Amide derivatives as lysophosphatidic acid receptor antagonists - Google Patents

Amide derivatives as lysophosphatidic acid receptor antagonists

Info

Publication number
SG11201601250TA
SG11201601250TA SG11201601250TA SG11201601250TA SG11201601250TA SG 11201601250T A SG11201601250T A SG 11201601250TA SG 11201601250T A SG11201601250T A SG 11201601250TA SG 11201601250T A SG11201601250T A SG 11201601250TA SG 11201601250T A SG11201601250T A SG 11201601250TA
Authority
SG
Singapore
Prior art keywords
receptor antagonists
acid receptor
amide derivatives
lysophosphatidic acid
lysophosphatidic
Prior art date
Application number
SG11201601250TA
Other languages
English (en)
Inventor
William Buffham
Hannah Canning
Richard Davenport
William Farnaby
Stephen Mack
Alka Parmar
Susanne Wright
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of SG11201601250TA publication Critical patent/SG11201601250TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201601250TA 2013-08-20 2014-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists SG11201601250TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1314926.5A GB201314926D0 (en) 2013-08-20 2013-08-20 Novel Compounds
PCT/GB2014/052558 WO2015025164A1 (en) 2013-08-20 2014-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists

Publications (1)

Publication Number Publication Date
SG11201601250TA true SG11201601250TA (en) 2016-03-30

Family

ID=49301993

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201601250TA SG11201601250TA (en) 2013-08-20 2014-08-20 Amide derivatives as lysophosphatidic acid receptor antagonists

Country Status (24)

Country Link
US (3) US10100018B2 (enExample)
EP (1) EP3036215A1 (enExample)
JP (1) JP6422974B2 (enExample)
KR (1) KR20160045797A (enExample)
CN (1) CN105473548B (enExample)
AR (1) AR097403A1 (enExample)
AU (1) AU2014310404B2 (enExample)
CA (1) CA2921742A1 (enExample)
CL (1) CL2016000387A1 (enExample)
CR (1) CR20160084A (enExample)
EA (1) EA028818B1 (enExample)
GB (1) GB201314926D0 (enExample)
HK (1) HK1225712A1 (enExample)
IL (1) IL243780A0 (enExample)
MA (1) MA38854B1 (enExample)
MX (1) MX2016001896A (enExample)
PE (1) PE20160284A1 (enExample)
PH (1) PH12016500322A1 (enExample)
SG (1) SG11201601250TA (enExample)
TN (1) TN2016000061A1 (enExample)
TW (1) TW201536722A (enExample)
UY (1) UY35708A (enExample)
WO (1) WO2015025164A1 (enExample)
ZA (1) ZA201600753B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314926D0 (en) * 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7173350B2 (ja) 2019-07-30 2022-11-16 大正製薬株式会社 Ｌｐａ１受容体を拮抗するウレア化合物
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR20240005892A (ko) 2021-05-11 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
AU2022405082B2 (en) 2021-12-08 2025-09-25 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2024252334A1 (en) * 2023-06-06 2024-12-12 Gpcr Therapeutics, Inc. Gpcr inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707641B1 (fr) * 1993-07-16 1995-08-25 Fournier Ind & Sante Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
ES2239203T3 (es) 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
TW200400930A (en) * 2002-06-26 2004-01-16 Ono Pharmaceutical Co Therapeutic agent for chronic disease
EP1553075B1 (en) * 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
IN2012DN00754A (enExample) * 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
WO2011037192A1 (ja) 2009-09-25 2011-03-31 アステラス製薬株式会社 置換アミド化合物
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
PH12012500542A1 (en) * 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
GB201314926D0 (en) 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds

Also Published As

Publication number Publication date
EA028818B1 (ru) 2018-01-31
CA2921742A1 (en) 2015-02-26
WO2015025164A1 (en) 2015-02-26
EP3036215A1 (en) 2016-06-29
AR097403A1 (es) 2016-03-09
CL2016000387A1 (es) 2016-12-16
PH12016500322A1 (en) 2016-05-02
MX2016001896A (es) 2016-05-26
US20160207880A1 (en) 2016-07-21
GB201314926D0 (en) 2013-10-02
US10100018B2 (en) 2018-10-16
KR20160045797A (ko) 2016-04-27
US9464060B2 (en) 2016-10-11
MA38854B1 (fr) 2018-05-31
US20150057298A1 (en) 2015-02-26
CN105473548A (zh) 2016-04-06
PE20160284A1 (es) 2016-04-27
EA201690390A1 (ru) 2016-08-31
MA38854A1 (fr) 2017-07-31
JP2016528274A (ja) 2016-09-15
CR20160084A (es) 2016-05-27
ZA201600753B (en) 2019-07-31
TW201536722A (zh) 2015-10-01
HK1225712A1 (zh) 2017-09-15
AU2014310404B2 (en) 2018-07-12
CN105473548B (zh) 2018-03-23
AU2014310404A1 (en) 2016-03-10
IL243780A0 (en) 2016-04-21
UY35708A (es) 2014-12-31
JP6422974B2 (ja) 2018-11-14
TN2016000061A1 (en) 2017-07-05
US20190010129A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
IL244943A0 (en) New amino pyrimidine histories
IL230913A0 (en) Lysophosphatidic acid receptor antagonists
SG11201506813QA (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
ZA201600753B (en) Amide derivatives as lysophosphatidic acid receptor antagonists
SG11201600473UA (en) Amino acid derivatives
IL239295A0 (en) History of indole carboxamides as 7x2p receptor antagonists
ZA201406085B (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
PT2935227T (pt) Amidas diazol como antagonistas do recetor ccr1
IL233485A0 (en) History of spiroindoline as gonadotropin-releasing hormone receptor antagonists
ZA201604490B (en) S1p3 antagonists
HUP1300139A2 (en) Phenoxypiperidine h3 antagonists
IL246091A0 (en) Opioid antagonist formulations
SG11201507990WA (en) Amine mixture
ZA201508209B (en) Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists
TH1601000893A (th) อนุพันธ์ของเอไมด์ที่เป็นรีเซพเตอร์ แอนตาโกนิสต์ของกรดไลโซฟอสฟาติดิก
GB201213698D0 (en) Receptor antagonists II
GB201213699D0 (en) Receptor antagonists II
GB201322181D0 (en) Feed formulation
GB201321280D0 (en) Feed formulation
GB201304666D0 (en) Dopamine receptor antagonist